Phibro Animal Health Corporation Company Profile (NASDAQ:PAHC)

Phibro Animal Health Corporation trades on the NASDAQ under the ticker symbol "PAHC."

Phibro Animal Health Corporation announced a quarterly dividend on Tuesday, July 25th. Investors of record on Wednesday, September 6th will be given a dividend of $0.10 per share on Wednesday, September 27th. This represents a $0.40 annualized dividend and a dividend yield of 1.00%. The ex-dividend date is Friday, September 1st. View Phibro Animal Health Corporation's Dividend History.

Phibro Animal Health Corporation (NASDAQ:PAHC) released its quarterly earnings data on Wednesday, November, 9th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.02. The business earned $188 million during the quarter, compared to analyst estimates of $188.85 million. Phibro Animal Health Corporation had a net margin of 8.49% and a return on equity of 54.68%. The firm's revenue was up .5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.44 earnings per share. View Phibro Animal Health Corporation's Earnings History.

Phibro Animal Health Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, August, 30th 2017. View Earnings Estimates for Phibro Animal Health Corporation.

6 brokerages have issued twelve-month price objectives for Phibro Animal Health Corporation's stock. Their predictions range from $21.00 to $36.00. On average, they expect Phibro Animal Health Corporation's stock price to reach $29.00 in the next year. View Analyst Ratings for Phibro Animal Health Corporation.

Here are some recent quotes from research analysts about Phibro Animal Health Corporation stock:

• 1. According to Zacks Investment Research, "Phibro ended third-quarter fiscal 2017 on a sluggish note, with earnings in line with the Zacks Consensus Estimate and declining year over year. Notably, the stock was trading below the Zacks categorized Medical Information Systems industry over the last three months. However post the earnings release the company’s share price shot up. This may be on account Phibro’s revenues increase on a year-over-year basis with Animal Health remaining the key contributing business. The company’s strong operating margin is also encouraging. Improved full-year earnings guidance is an upside too. On the flip side, additionally, currency fluctuations, sluggish macro-economic conditions and a tough competitive scenario are major concerns of the company. This fails to boost market confidence on the stock." (5/11/2017)
• 2. Piper Jaffray Companies analysts commented, "We continue to favor shares of PAHC as a top small cap idea in our ag space, where we see potential for upward revisions to guidance in 2H17 following the 2Q earnings beat and management reaffirming guidance. Positively, the Animal Health segment grew in the December-ending quarter despite ongoing headwinds in MFAs, supporting our thesis around the resilience of the animal health industry. We are lifting our FY17 EPS estimate to $1.45 at the top of the guidance range and we see potential earnings upside in 2H17 from growth outside of MFAs and in other geographies like Brazil. We see multiple expansion opportunity with some of the MFA overhang on the stock removed after the resilient 2Q results and our price target moves to $34 based on 21X FY18E EPS of $1.60. We reiterate our Overweight rating." (2/8/2017)

Some companies that are related to Phibro Animal Health Corporation include Cantel Medical Corp. (CMD), Portola Pharmaceuticals (PTLA), Hutchison China MediTech Limited (HCM), INC Research Holdings (INCR), Sage Therapeutics (SAGE), Wright Medical Group N.V. (WMGI), Chemed Corp. (CHE), AveXis (AVXS), LivaNova PLC (LIVN), Globus Medical (GMED), Juno Therapeutics (JUNO), Nektar Therapeutics (NKTR), Penumbra (PEN), Ligand Pharmaceuticals Incorporated (LGND), Evotec AG (EVTCY), BeiGene (BGNE), Agios Pharmaceuticals (AGIO) and Intercept Pharmaceuticals (ICPT).

Phibro Animal Health Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BFI COMPANY ., LLC (51.80%), BlackRock Inc. (7.21%), Vanguard Group Inc. (4.49%), Denver Investment Advisors LLC (1.74%), FMR LLC (1.47%) and State Street Corp (1.22%). Company insiders that own Phibro Animal Health Corporation stock include Bfi Co, Llc, Daniel A Welch, Daniel M Bendheim, Dean J Warras, E Thomas Corcoran, Gerald K Carlson, Jack Bendheim, Larry Lee Miller and Thomas G Dagger. View Institutional Ownership Trends for Phibro Animal Health Corporation.

Phibro Animal Health Corporation's stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Alliancebernstein L.P., Spark Investment Management LLC, Wells Fargo & Company MN, First Mercantile Trust Co., Menta Capital LLC, State Street Corp and Tudor Investment Corp ET AL. Company insiders that have sold Phibro Animal Health Corporation stock in the last year include Bfi Co, Llc, Daniel A Welch, Daniel M Bendheim, Gerald K Carlson, Jack Bendheim, Larry Lee Miller and Thomas G Dagger. View Insider Buying and Selling for Phibro Animal Health Corporation.

Phibro Animal Health Corporation's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, AJO LP, FMR LLC, Ameriprise Financial Inc., Mckinley Capital Management LLC Delaware, Goldman Sachs Group Inc., Acadian Asset Management LLC and Vanguard Group Inc.. View Insider Buying and Selling for Phibro Animal Health Corporation.

Shares of Phibro Animal Health Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Phibro Animal Health Corporation stock can currently be purchased for approximately $39.85.